FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2324427928> ?p ?o ?g. }

• W2324427928 endingPage "73" @default.
• W2324427928 startingPage "68" @default.
• W2324427928 abstract "Objectives The aim of this retrospective study was to analyse the efficacy of gemcitabine-oxaliplatin (gemox) or 5-fluorouracil-oxaliplatin (folfox) in the treatment of metastatic pulmonary carcinoid tumors. Patients and methods 45 patients were included in two tertiary referral centers between January 1999 and January 2013. Typical, atypical carcinoids or not otherwise specified carcinoids were diagnosed according to WHO criteria in 19%, 57%, and 24% of cases by two expert pathologists. Patients had synchronous (38%) or metachronous (62%) metastastic disease (median of 2 (1–5) metastatic sites). Seventy-nine percent had progressive disease before start of chemotherapy. Treatment consisted of: gemcitabine 1000 mg/m2 and oxaliplatin 100 mg/m2 every 2 weeks (gemox regimen, n = 24) or 5-fluorouracil (5-FU) (400 mg/m2 in bolus injection and 5-FU 2400 mg/m2 in 46 h-infusion) and oxaliplatin 85 mg/m2 (folfox regimen, n = 21) every 2 weeks. Tumor response was assessed according to RECIST criteria every 8–12 weeks. Progression free survival and overall survival were assessed using Kaplan Meier curves. Results Patients received oxaliplatin-based chemotherapy in first-line (20%), second-line (33%), or post-second-line (47%) systemic treatment. The median number of cycles was 8 (1–12). Nine (20%) stopped oxaliplatin before 8 cycles because of toxicity. Nine patients (20%) had a partial response and 29 (64%) had stable disease. Median progression free survival (PFS) was 15 (6–25) months. Median overall survival (OS) was 34 (21–49) months. No significant difference was observed in response and PFS between either regimens. Conclusions Our results suggest that either gemcitabine-oxaliplatin or 5-fluorouracil-oxaliplatin combinations are attractive chemotherapy regimen in metastatic pulmonary carcinoid tumors." @default.
• W2324427928 created "2016-06-24" @default.
• W2324427928 creator A5001498932 @default.
• W2324427928 creator A5007925107 @default.
• W2324427928 creator A5008235770 @default.
• W2324427928 creator A5017481421 @default.
• W2324427928 creator A5023956790 @default.
• W2324427928 creator A5024164679 @default.
• W2324427928 creator A5028596081 @default.
• W2324427928 creator A5029587078 @default.
• W2324427928 creator A5049423456 @default.
• W2324427928 creator A5050152335 @default.
• W2324427928 creator A5050532099 @default.
• W2324427928 creator A5067116958 @default.
• W2324427928 creator A5085121407 @default.
• W2324427928 date "2016-06-01" @default.
• W2324427928 modified "2023-10-06" @default.
• W2324427928 title "Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors" @default.
• W2324427928 cites W155301972 @default.
• W2324427928 cites W1575433014 @default.
• W2324427928 cites W1581678255 @default.
• W2324427928 cites W1728181864 @default.
• W2324427928 cites W1981846777 @default.
• W2324427928 cites W1992109464 @default.
• W2324427928 cites W2011916383 @default.
• W2324427928 cites W2042265119 @default.
• W2324427928 cites W2062011075 @default.
• W2324427928 cites W2062776919 @default.
• W2324427928 cites W2065387828 @default.
• W2324427928 cites W2078366633 @default.
• W2324427928 cites W2080301934 @default.
• W2324427928 cites W2097924418 @default.
• W2324427928 cites W2109498035 @default.
• W2324427928 cites W2112165394 @default.
• W2324427928 cites W2118672029 @default.
• W2324427928 cites W2121079285 @default.
• W2324427928 cites W2130735070 @default.
• W2324427928 cites W2149214723 @default.
• W2324427928 cites W2164252602 @default.
• W2324427928 cites W2209368665 @default.
• W2324427928 cites W2251438188 @default.
• W2324427928 cites W2336877383 @default.
• W2324427928 cites W2468894750 @default.
• W2324427928 doi "https://doi.org/10.1016/j.lungcan.2016.03.018" @default.
• W2324427928 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27133753" @default.
• W2324427928 hasPublicationYear "2016" @default.
• W2324427928 type Work @default.
• W2324427928 sameAs 2324427928 @default.
• W2324427928 citedByCount "26" @default.
• W2324427928 countsByYear W23244279282016 @default.
• W2324427928 countsByYear W23244279282017 @default.
• W2324427928 countsByYear W23244279282018 @default.
• W2324427928 countsByYear W23244279282019 @default.
• W2324427928 countsByYear W23244279282020 @default.
• W2324427928 countsByYear W23244279282021 @default.
• W2324427928 countsByYear W23244279282022 @default.
• W2324427928 countsByYear W23244279282023 @default.
• W2324427928 crossrefType "journal-article" @default.
• W2324427928 hasAuthorship W2324427928A5001498932 @default.
• W2324427928 hasAuthorship W2324427928A5007925107 @default.
• W2324427928 hasAuthorship W2324427928A5008235770 @default.
• W2324427928 hasAuthorship W2324427928A5017481421 @default.
• W2324427928 hasAuthorship W2324427928A5023956790 @default.
• W2324427928 hasAuthorship W2324427928A5024164679 @default.
• W2324427928 hasAuthorship W2324427928A5028596081 @default.
• W2324427928 hasAuthorship W2324427928A5029587078 @default.
• W2324427928 hasAuthorship W2324427928A5049423456 @default.
• W2324427928 hasAuthorship W2324427928A5050152335 @default.
• W2324427928 hasAuthorship W2324427928A5050532099 @default.
• W2324427928 hasAuthorship W2324427928A5067116958 @default.
• W2324427928 hasAuthorship W2324427928A5085121407 @default.
• W2324427928 hasConcept C121608353 @default.
• W2324427928 hasConcept C126322002 @default.
• W2324427928 hasConcept C141071460 @default.
• W2324427928 hasConcept C143998085 @default.
• W2324427928 hasConcept C2776694085 @default.
• W2324427928 hasConcept C2778260052 @default.
• W2324427928 hasConcept C2778336483 @default.
• W2324427928 hasConcept C2778822529 @default.
• W2324427928 hasConcept C2779984678 @default.
• W2324427928 hasConcept C2780258809 @default.
• W2324427928 hasConcept C2780456651 @default.
• W2324427928 hasConcept C2780739268 @default.
• W2324427928 hasConcept C2780962732 @default.
• W2324427928 hasConcept C2781413609 @default.
• W2324427928 hasConcept C526805850 @default.
• W2324427928 hasConcept C71924100 @default.
• W2324427928 hasConcept C90924648 @default.
• W2324427928 hasConceptScore W2324427928C121608353 @default.
• W2324427928 hasConceptScore W2324427928C126322002 @default.
• W2324427928 hasConceptScore W2324427928C141071460 @default.
• W2324427928 hasConceptScore W2324427928C143998085 @default.
• W2324427928 hasConceptScore W2324427928C2776694085 @default.
• W2324427928 hasConceptScore W2324427928C2778260052 @default.
• W2324427928 hasConceptScore W2324427928C2778336483 @default.
• W2324427928 hasConceptScore W2324427928C2778822529 @default.
• W2324427928 hasConceptScore W2324427928C2779984678 @default.
• W2324427928 hasConceptScore W2324427928C2780258809 @default.

• next